Nithyadevi Duraisamy

Dr. Nithyadevi Duraisamy

Dept. of Computer Science and Eng / Dept. of Pharmacy, Long Island University, Brooklyn, New York, USA
orcid
Open for Collaboration

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 October 2024 in Frontiers in Veterinary Science
Verified
Journal Article
Open access
PDF file
Nithyadevi DuraisamyNithyadevi Duraisamy
Nithyadevi Duraisamy
MKMohd Yasir Khan
Mohd Yasir Khan
ASAbid Ullah Shah
Abid Ullah Shah
REReda Nacif Elalaoui
Reda Nacif Elalaoui
MCMohammed Cherkaoui
Mohammed Cherkaoui
MHMaged Hemida
Maged Hemida
Introduction: BCoV is one of the significant causes of enteritis in young calves; it may also be responsible for many respiratory outbreaks in young calves. BCoV participates in the development of bovine respiratory disease complex in association with other bacterial pathogens. Our study aimed (1) to map the immunogenic epitopes (B and T cells) within the major BCoV structural proteins. These epitopes are believed to induce a robust immune response through the interaction with major histocompatibility complex (MHC class II) molecules (2) to design some novel BCoV multiepitope-based vaccines.Materials and Methods: The goal is achieved through several integrated in silico prediction computational tools to map these epitopes within the major BCoV structural proteins. The final vaccine was constructed in conjugation with the Choleratoxin B toxin as an adjuvant. The tertiary structure of each vaccine construct was modeled through the AlphaFold2 tools. The constructed vaccine was linked to some immunostimulants such as Toll-like receptors (TLR2 and TLR4). We also predicted the affinity binding of these vaccines with this targeted protein using molecular docking. The stability and purity of each vaccine construct were assessed using the Ramachandran plot and the Z-score values. We created the in silico cloning vaccine constructs using various expression vectors through vector builder and Snap gene.Results and discussion: The average range of major BCoV structural proteins was detected within the range of 0.4 to 0.5, which confirmed their antigen and allergic properties. The binding energy values were detected between −7.9 and −9.4 eV and also confirmed their best interaction between our vaccine construct and Toll-like receptors. Our in silico cloning method expedited the creation of vaccine constructs and established a strong basis for upcoming clinical trials and experimental validations.Conclusion: Our designed multiepitope vaccine candidates per each BCoV structural protein showed high antigenicity, immunogenicity, non-allergic, non-toxic, and high-water solubility. Further studies are highly encouraged to validate the efficacy of these novel BCoV vaccines in the natural host.

10 July 2025 in Viruses
Verified
Journal Article
Open access
PDF file
Mohd Yasir KhanMohd Yasir Khan
Mohd Yasir Khan
ASAbid Ullah Shah
Abid Ullah Shah
Nithyadevi DuraisamyNithyadevi Duraisamy
Nithyadevi Duraisamy
MCMohammed Cherkaoui
Mohammed Cherkaoui
MHMaged Hemida
Maged Hemida
(1) Background: The highly pathogenic avian influenza virus H5N1 clade 2.3.4.4b is an emerging threat that poses a great risk to the poultry industry. A few human cases have been linked to the infection with this clade in many parts of the world, including the USA. Unfortunately, there are no specific vaccines or antiviral drugs that could help prevent and treat the infection caused by this virus in birds. Our major objective is to identify/repurpose some (novel/known) antiviral compounds that may inhibit viral replication by targeting some key viral proteins. (2) Methods: We used state-of-the-art machine learning tools such as molecular docking and MD-simulation methods from Biovia Discovery Studio (v24.1.0.321712). The key target proteins such as hemagglutinin (HA), neuraminidase (NA), Matrix-2 protein (M2), and the cap-binding domain of PB2 (PB2/CBD) homology models were validated through structural assessment via DOPE scores, Ramachandran plots, and Verify-3D metrics, ensuring reliable structural representations, confirming their reliability for subsequent in silico approaches. These approaches include molecular docking followed by molecular dynamics simulation for 50 nanoseconds (ns), highlighting the structural stability and compactness of the docked complexes. (3) Results: Molecular docking revealed strong binding affinities for both sofosbuvir and GS441524, particularly with the NA and PB2/CBD protein targets. Among them, GS441524 exhibited superior interaction scores and a greater number of hydrogen bonds with key functional residues of NA and PB2/CBD. The MM-GBSA binding free energy calculations further supported these findings, as GS441524 displayed more favorable binding energies compared to several known standard inhibitors, including F0045S for HA, Zanamivir for NA, Rimantadine and Amantadine for M2, and PB2-39 for PB2/CBD. Additionally, 50 ns molecular dynamics simulations highlighted the structural stability and compactness of the GS441524-PB2/CBD complex, further supporting its potential as a promising antiviral candidate. Furthermore, hydrogen bond monitor analysis over the 50 ns simulation confirmed persistent and specific interactions between the ligand and proteins, suggesting that GS441524 may effectively inhibit the NA, and PB2/CBD might potentially disrupt PB2-mediated RNA synthesis. (4) Conclusions: Our findings are consistent with previous evidence supporting the antiviral activity of certain nucleoside analog inhibitors, including GS441524, against various coronaviruses. These results further support the potential repurposing of GS441524 as a promising therapeutic candidate against H5N1 avian influenza clade 2.3.4.4b. However, further functional studies are required to validate these in silico predictions and support the inhibitory action of GS441524 against the targeted proteins of H5N1, specifically clade 2.3.4.4b.

22 August 2025 in Viruses
Verified
Journal Article
Open access
PDF file
Nithyadevi DuraisamyNithyadevi Duraisamy
Nithyadevi Duraisamy
ASAbid Ullah Shah
Abid Ullah Shah
Mohd Yasir KhanMohd Yasir Khan
Mohd Yasir Khan
MCMohammed Cherkaoui
Mohammed Cherkaoui
MHMaged Hemida
Maged Hemida
The presently used vaccines do not offer solid immunity/protection against the currently circulating strains of the H5N1 viruses. We aim to design a pan-H5N1 vaccine that protects birds against the presently circulating clade 2.3.4.4b in chickens. We used AI tools, including epitope mapping, molecular docking, and immune simulation, to design a multiepitope DNA vaccine including the top-ranked B and T cell epitopes within four major proteins (HA, NA, NP, and M2) of H5N1 clade 2.3.4.4b. We selected the top-ranked 12 epitopes and linked them together using linkers. The designed vaccine is linked to IL-18 as an adjuvant. The molecular docking results showed a high binding affinity of those predicted epitopes from the MHC I and MHC II classes of molecules with chicken alleles. The immune simulation results showed that the designed vaccine has the potential to stimulate the host immune response, including antibody and cell-mediated immunity in chickens and other birds. We believe this vaccine is going to be a universal vaccine that offers good protection against HPAI-H5N1 clade 2.3.4.4b. We are reporting the successful molecular cloning of a recombinant multiepitope-based vaccine spanning some key epitopes within some key proteins of the currently circulating H5N1 clade 2.3.4.4b. These designed vaccines could be a great positive impact on the protection of birds and various species of animals, as well as humans, against the HP-H5N1 influenza virus. Further studies are required to validate this vaccine candidate in chickens.

30 July 2025 in PeerJ
Verified
Journal Article
Open access
PDF file
MKMohd Yasir Khan
Mohd Yasir Khan
ASAbid Ullah Shah
Abid Ullah Shah
Nithyadevi DuraisamyNithyadevi Duraisamy
Nithyadevi Duraisamy
NMNadine Moawad
Nadine Moawad
REReda Nacif ElAlaoui
Reda Nacif ElAlaoui
MHMaged Hemida
Maged Hemida
Background: Feline infectious peritonitis virus (FIPV) is one of cats’ most serious viral infections. The FIPV infection induces a complicated syndrome in the affected cats, including immunosuppression and severe inflammatory conditions. Unfortunately, vaccines are unable to provide complete prevention in cats from getting infected with these viral infections. There is ongoing research on preparing antiviral therapies against FIPV in cats. However, these are still in clinical trials and have not been fully approved by the drug authorities in many countries, including the USA. Targeting the main viral proteases is one of the promising trends in the drug design of many viral diseases, including coronaviruses. The main goal of the current study was to repurpose and test the efficacy of some known antiviral drugs to treat FIPV infection in cats by targeting the FIPV main protease (Mpro). Methods: We used the in-silico prediction and molecular docking tools to screen and identify some drugs targeting FIPV-MPro to achieve these goals. The research method was started by building a screening pharmacokinetic associated variables of the compound, then used to design a new potential inhibitor by employing the docking and molecular dynamic simulation to evaluate the interaction of all complexes using the standard dynamics cascade protocol of Biovia Discovery studio. Results: Our results show that out of the 15 antiviral and immunomodulatory compounds, the top-ranked inhibitors for the FIPV-Mpro are reference standard inhibitor (N3), Sofosbuvir, and the GS-441524, out of which GS-441524 was suggested as Mpro-inhibitor on the basis of further investigation through molecular dynamics simulation method. In conclusion, our results confirmed the potential applications of the predicted FIPV-Mpro inhibitors either independently or in combination with other immune-modulatory compounds. Further in vitro and in vivo studies are encouraged to test the efficacy of these identified compounds as potent inhibitors for the Mpro of the FIPV in cats. This study will pave the way for the development of novel drugs that treat FIPV infection in cats.

Verified
Journal Article
Open access
PDF file
Mohd Yasir KhanMohd Yasir Khan
Mohd Yasir Khan
ASAbid Ullah Shah
Abid Ullah Shah
Nithyadevi DuraisamyNithyadevi Duraisamy
Nithyadevi Duraisamy
REReda Nacif Elalaoui
Reda Nacif Elalaoui
MCMohammed Cherkaoui
Mohammed Cherkaoui
MHMaged Hemida
Maged Hemida
Bovine coronavirus (BCoV) exhibits dual tissue tropism, infecting both the respiratory and enteric tracts of cattle. Viral entry into host cells requires a coordinated interaction between viral and host proteins. However, the specific cellular receptors and co-receptors facilitating BCoV entry remain poorly understood. Similarly, the roles of host proteases such as Furin, TMPRSS2, and Cathepsin-L (CTS-L), known to assist in the replication of other coronaviruses, have not been extensively explored for BCoV. This study aims to identify novel BCoV receptors and host proteases that modulate viral replication and tissue tropism. Bovine cell lines were infected with BCoV isolates from enteric and respiratory origins, and the host cell gene expression profiles post-infection were analyzed using next-generation sequencing (NGS). Differentially expressed genes encoding potential receptors and proteases were further assessed using in-silico prediction and molecular docking analysis. These analyses focused on known coronavirus receptors, including ACE2, NRP1, DPP4, APN, AXL, and CEACAM1, to identify their potential roles in BCoV infection. Validation of these findings was performed using the qRT-PCR assays targeting individual genes. We confirmed the gene expression profiles of these receptors and enzymes in some BCoV (+/−) lung tissues. Results revealed high binding affinities of 9-O-acetylated sialic acid and NRP1 to BCoV spike (S) and hemagglutinin-esterase (HE) proteins compared to ACE2, DPP4, and CEACAM1. Additionally, Furin and TMPRSS2 were predicted to interact with the BCoV-S polybasic cleavage site (RRSRR|A), suggesting their roles in S glycoprotein activation. This is the first study to explore the interactions of BCoV with multiple host receptors and proteases. Functional studies are recommended to confirm their roles in BCoV infection and replication.

1 March 2013 in Advanced Materials Research
Verified
Journal Article
Closed access
PDF file
Nithyadevi DuraisamyNithyadevi Duraisamy
Nithyadevi Duraisamy
RRRamasamy Thangavelu Rajendrakumar
Ramasamy Thangavelu Rajendrakumar
Pure TiO2 nanoparticles were synthesized using Titanium (IV)-n-butoxide as Titanium precursor and Sn doping was performed by adding Tin (II) ethylhexanate (Sn precursor) in Titanium precursor by Sol-gel method. The morphology of nanoparticles was examined by XRD and SEM analysis. The XRD analysis shows the formation of mixture phases (anatase and brookite) for pure TiO2. Addition of lower Sn precursor concentration resulted in the formation of Sn doped TiO2 nanoparticles. On increasing the Sn precursor favours the growth of TiO2-SnO2 nanocomposites. It is interesting to observe the fraction of brookite phase in TiO2 decreases by increasing the Sn precursor concentration. The photocatalytic activity test for pure TiO2, pure SnO2, Sn doped TiO2 nanoparticles and TiO2-SnO2 nanocomposites were carried out for Methylene blue (MB) solution. Both Sn doped TiO2 nanoparticles and TiO2-SnO2 nanocomposites show faster photocatalytic degradation than pure TiO2 nanoparticles due to suppression of brookite phase by addition of Sn precursor.